Drugs / Octreotide
Octreotide
also known as
octreotide acetate · Octreotide LAR · Sandostatin · Sandostatin LAR · Sandostatin LAR Depot · Long-acting octreotide · OCT · OctLAR · +16 more
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed acromegaly 3 milestones | |||||
| Filed | US (FDA) | CAM2029 | acromegaly | 2026-07-17 | “accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly.” camurus.com ↗ |
| Rejected (CRL) | US (FDA) | Oclaiz | acromegaly | 2026-06-10 | “issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (Oclaiz™), octreotide extended-release injection, for the treatment of patients...” camurus.com ↗ |
| Filed | US (FDA) | Oclaiz | acromegaly | 2026-01-09 | “accepted for review the company’s resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), octreotide extended-release injection, for the treatment of patients...” camurus.com ↗ |
| Approved Indication not stated 4 milestones | |||||
| Approved | EU (EMA) | Mycapssa | — | 2022-12-02 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | SANDOSTATIN LAR | — | 2006-05-10 – 2008-03-03 | fda.gov ↗ |
| Label expansion | US (FDA) | SANDOSTATIN | — | 1994-05-03 | fda.gov ↗ |
| Approved | US (FDA) | SANDOSTATIN | — | 1988-10-21 | fda.gov ↗ |
Trials 135 · started per year
today
US approved 1988
EU approved 2022
1
1
3
3
5
3
1
9
3
4
13
8
7
4
4
3
4
4
4
9
6
5
4
4
5
2
3
2
3
3
2
198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05683444 | Jul 2020 → Mar 2021 | lymphatic system disorder | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 113 trials · 1 met primary | ||||||
| Phase 1 | NCT05761431 | Mar → Jun 2023 | acromegaly | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05340192 | Sep 2019 → Feb 2020 | — | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT03798912 | Jul 2019 → Feb 2020 | — | RANI Therapeutics | Completed | Met primary |
| Phase 1 | NCT03031535 | Jan → Mar 2017 | — | Dauntless Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02195635 | Jul → Oct 2014 | — | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01707225 | Feb 2013 → Oct 2014 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1 | NCT02217839 | Apr 2012 → Jan 2013 | — | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT01086982 | Mar → May 2010 | acromegaly | Azidus Brasil | Suspended | No outcome recorded |
| Phase 1 | NCT00584298 | Jan 2008 → Apr 2009 | irritable bowel syndrome | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00432068 | Jan 2007 → Jun 2010 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | Mixed |
| Phase 1 | NCT00008073 | Jan 1996 → May 2002 | cancer of unknown primary site | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT02217826 | ? → Apr 2014 | — | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1/25 trials · 1 missed | ||||||
| Phase 1/2 | NCT00884715 | Jul 2009 → Nov 2011 | carcinoid syndrome | Endo USA Inc., a Keenova Therapeutics Company | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00463983 | Oct 2006 → Jan 2010 | idiopathic pulmonary fibrosis | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 1/2 | NCT00274170 | Jan 2006 → Feb 2007 | migraine disorder | C.R.Darnall Army Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT01188733 | Jun 1998 → Jul 2000 | cirrhosis of liver, esophageal varices, portal hypertension | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00262470 | Apr 1997 → Dec 2029 expected | cardiac rhythm disease | Satish R. Raj | Active not recruiting | Missed primary |
| Phase 241 trials · 4 missed | ||||||
| Phase 2 | NCT06085976 | Aug 2023 → Aug 2025 | hepatocellular carcinoma | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase 2 | NCT04871204 | Jun 2021 → Feb 2024 | esophageal cancer, gastric cancer | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04027348 | Jun 2019 → Sep 2021 | intestinal obstruction | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03541447 | Dec 2018 → Dec 2021 | autosomal dominant polycystic kidney disease | Mario Negri Institute for Pharmacological Research | Completed | Mixed |
| Phase 2 | NCT03179995 | Jul 2017 → Feb 2020 | — | Fox Chase Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT04129255 | Jun 2017 → Dec 2019 | neuroendocrine neoplasm | National Cancer Institute, Naples | Completed | No outcome recorded |
| Phase 2 | NCT02874326 | Oct 2016 → Jul 2018 | anemia, hereditary hemorrhagic telangiectasia | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02916433 | Sep 2016 → Feb 2018 | — | Danbury Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01587222 | Jul 2016 → Jul 2017 | hepatorenal syndrome, kidney failure | Anna Cruceta | Withdrawn | No outcome recorded |
| Phase 2 | NCT02668588 | Oct 2015 → Jul 2016 | — | Chemi S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT02437825 | Oct 2015 → Jun 2021 | cysts and fistulae of the face and oral cavity | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 2 | NCT02409849 | Apr 2015 → Nov 2018 | digestive system carcinoma, esophageal neuroendocrine tumor | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT02333565 | Jan 2015 → Jan 2019 | meningioma | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 2 | NCT02299089 | Jan 2015 → May 2016 | acromegaly, neuroendocrine neoplasm | Camurus AB | Completed | No outcome recorded |
| Phase 2 | NCT02294786 | Dec 2014 → Oct 2017 | cancer | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 2 | NCT02294006 | Jun 2014 → Jun 2021 | pancreatic neuroendocrine tumor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Unknown | No outcome recorded |
| Phase 2 | NCT02101385 | Apr 2014 → Feb 2021 | breast cancer | Bryan Schneider, MD | Completed | Missed primary |
| Phase 2 | NCT02217800 | Nov 2013 → Mar 2014 | acromegaly | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 2 | NCT02235987 | Oct → Dec 2012 | acromegaly | Aspireo Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 2 | NCT01469338 | Jul 2012 → Oct 2014 | diarrheal disease, hormone-resistant prostate carcinoma | University of Southern California | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01480986 | Sep 2011 → Sep 2012 | — | Peking University | Completed | No outcome recorded |
| Phase 2 | NCT01229943 | Oct 2010 → Sep 2014 | VIPoma, pancreatic gastrinoma, pancreatic neuroendocrine tumor G1 | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00987168 | May 2009 → Apr 2011 | congenital isolated hyperinsulinism | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00510224 | Jul 2007 → Aug 2009 | prostate cancer | University of California, San Francisco | Terminated | Missed primary |
| Phase 2 | NCT00913055 | Feb → May 2007 | acromegaly | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT00990535 | Jan 2006 → Dec 2007 | multiple endocrine neoplasia, pancreatic neoplasm, respiratory tract neoplasm, thymus neoplasm | Federico II University | Completed | No outcome recorded |
| Phase 2 | NCT01203306 | Jan 2006 → May 2009 | neuroendocrine carcinoma | University of Turin, Italy | Unknown | No outcome recorded |
| Phase 2 | NCT00332969 | Sep 2005 → Oct 2010 | thymoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00332696 | Sep 2005 → Sep 2008 | intestinal obstruction, peritoneal carcinomatosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00257426 | Jul 2005 → Feb 2007 | liver cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00113360 | Jan 2005 → Jul 2009 | pancreatic endocrine carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00088582 | Mar 2004 → Oct 2005 | acromegaly | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00166725 | Feb 2004 → ? | prostate cancer | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00953394 | Feb 2002 → Feb 2006 | neuroendocrine neoplasm | University of Turin, Italy | Completed | No outcome recorded |
| Phase 2 | NCT00250796 | Sep 2000 → Jan 2006 | cancer, liver disorder | University of New Mexico | Completed | No outcome recorded |
| Phase 2 | NCT00005906 | Jun 2000 → Apr 2008 | lymphangioleiomyomatosis, lymphangiomyoma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00004895 | Oct 1999 → Oct 2002 | bile duct cancer, colorectal cancer, gastric cancer, gastrointestinal stromal tumor +5 | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00003283 | Oct 1998 → Sep 2003 | combined thymoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002779 | Feb 1998 → Jul 2000 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00004327 | Jan 1995 → ? | hereditary hemorrhagic telangiectasia | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2 | NCT00227773 | — | carcinoid tumor, pancreatic endocrine carcinoma | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Phase 2/38 trials · 2 met primary | ||||||
| Phase 2/3 | NCT07165886 | Aug 2025 → Aug 2028 expected | digestive system neuroendocrine neoplasm | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06062719 | Aug 2023 → Sep 2024 | — | National Hepatology & Tropical Medicine Research Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT05281328 | Jun 2022 → Feb 2025 overdue | liver disorder | Camurus AB | Active not recruiting | Met primary |
| Phase 2/3 | NCT02119013 | Jan 2009 → Sep 2013 | autosomal dominant polycystic kidney disease | Federico II University | Completed | No outcome recorded |
| Phase 2/3 | NCT02119052 | Jan 2009 → Sep 2013 | autosomal dominant polycystic kidney disease | Federico II University | Completed | Met primary |
| Phase 2/3 | NCT00495846 | Apr 2007 → Apr 2008 | hepatocellular carcinoma | Federico II University | Completed | No outcome recorded |
| Phase 2/3 | NCT00240045 | Oct 2005 → Jul 2007 | hepatorenal syndrome | University of Alberta | Completed | No outcome recorded |
| Phase 2/3 | NCT00742339 | May 2005 → Oct 2013 | cirrhosis of liver, hepatorenal syndrome | University of Padova | Terminated | No outcome recorded |
| Phase 334 trials · 5 met primary · 6 missed | ||||||
| Phase 3 | NCT07842172 | Nov 2026 → Nov 2034 expected | digestive system neuroendocrine neoplasm | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07623824 | May 2026 → Jul 2029 expected | acromegaly | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06930625 | Nov 2025 → Jun 2028 expected | acromegaly | Debiopharm International SA | Recruiting | No outcome recorded |
| Phase 3 | NCT05050942 | Oct 2021 → Jul 2026 overdue | digestive system neuroendocrine neoplasm | Camurus AB | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04125836 | Oct 2019 → Apr 2025 | acromegaly | Camurus AB | Completed | Met primary |
| Phase 3 | NCT04076462 | Aug 2019 → May 2023 | acromegaly | Camurus AB | Completed | Met primary |
| Phase 3 | NCT02685709 | Feb 2016 → Oct 2020 | acromegaly | Chiasma, Inc. | Completed | Met primary |
| Phase 3 | NCT01412424 | Mar 2012 → May 2014 | acromegaly | Chiasma, Inc. | Completed | Met primary |
| Phase 3 | NCT01377246 | May 2011 → Oct 2017 | autosomal dominant polycystic kidney disease | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 3 | NCT01295060 | Feb 2011 → Apr 2012 | acromegaly | Endo USA Inc., a Keenova Therapeutics Company | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00582426 | Apr 2008 → Sep 2010 | chemotherapy-induced toxicity | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00569127 | Dec 2007 → Jan 2015 overdue | colorectal neuroendocrine tumor G1, gastric neuroendocrine tumor G1 | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 3 | NCT00635765 | Oct 2007 → Jun 2009 | acromegaly | Ambrilia Biopharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00309283 | Apr 2006 → Jan 2012 | autosomal dominant polycystic kidney disease | Mario Negri Institute for Pharmacological Research | Completed | Mixed |
| Phase 3 | NCT00372697 | Dec 2005 → Oct 2007 | acromegaly | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00248131 | Nov 2005 → Jul 2006 | diabetic retinopathy | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00248157 | Nov 2005 → May 2006 | diabetic retinopathy | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00182754 | Oct 2005 → Sep 2009 | metastatic malignant neoplasm | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 3 | NCT00804297 | Jun 2005 → Jan 2007 | diabetes mellitus, hypoglycemia | Albert Einstein Healthcare Network | Completed | No outcome recorded |
| Phase 3 | NCT00175305 | Aug 2004 → Oct 2007 | Prader-Willi syndrome, obesity, hyperphagia, and developmental delay | University of British Columbia | Terminated | No outcome recorded |
| Phase 3 | NCT00092287 | Jul → Oct 2004 | carcinoid syndrome | Ipsen | Terminated | No outcome recorded |
| Phase 3 | NCT00075868 | Dec 2003 → Aug 2006 | anus cancer, enteritis | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00170742 | Dec 2003 → May 2006 | proliferative diabetic retinopathy | Novartis | Terminated | No outcome recorded |
| Phase 3 | NCT00128232 | Dec 2002 → Aug 2004 | acromegaly | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00225979 | Nov 2002 → Mar 2005 | acromegaly | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00241020 | Jun 2002 → Oct 2005 | hepatocellular carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00033605 | Apr 2002 → Jul 2006 | cervical cancer, colorectal cancer, diarrheal disease, endometrial cancer +6 | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 3 | NCT00171873 | Sep 2001 → Jun 2008 | neuroendocrine neoplasm | Carmen Schade-Brittinger | Completed | Met primary |
| Phase 3 | NCT00130845 | Feb 2000 → Dec 2005 | diabetic retinopathy | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00006269 | Dec 1999 | colorectal cancer, diarrheal disease | Novartis | Terminated | No outcome recorded |
| Phase 3 | NCT00131144 | Nov 1999 → Dec 2005 | diabetic retinopathy | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00386984 | Oct 1999 → Feb 2003 | hepatocellular carcinoma | University Hospital Freiburg | Completed | No outcome recorded |
| Phase 3 | NCT00002967 | May 1997 → Mar 2006 | female breast carcinoma | NSABP Foundation Inc | Completed | Missed primary |
| Phase 3 | NCT00003057 | Mar 1997 → May 2000 | colorectal cancer, diarrheal disease | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 419 trials · 1 met primary · 5 missed | ||||||
| Phase 4 | NCT07262957 | Sep 2025 → Sep 2027 expected | ampulla of vater adenocarcinoma, cholangiocarcinoma, cystic neoplasm, neuroendocrine neoplasm +3 | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 4 | NCT05199038 | Jun 2022 → Jun 2023 | esophageal varices | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT04353193 | Jun 2020 → Feb 2022 | cirrhosis of liver | Juan A. Arnaiz | Unknown | No outcome recorded |
| Phase 4 | NCT03624517 | Sep 2018 → Dec 2024 | cirrhosis of liver, esophageal varices with bleeding | Medical University of South Carolina | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT03289741 | Sep 2017 → Apr 2023 | neuroendocrine neoplasm | Memorial Sloan Kettering Cancer Center | Completed | Missed primary |
| Phase 4 | NCT04140409 | Feb 2016 → Jun 2019 | carcinoid syndrome, neuroendocrine neoplasm | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02032784 | Mar 2014 → Jun 2018 | adenoma | AdventHealth | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02427295 | Mar 2014 → Dec 2018 | acromegaly | Asan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01917773 | Aug 2013 → Jun 2014 | constipation disorder, intestinal motility disease | Indiana University | Completed | Missed primary |
| Phase 4 | NCT01301222 | Sep 2010 → Sep 2014 | pancreas disorder | PVS Memorial Hospital | Completed | Missed primary |
| Phase 4 | NCT00552071 | Jul 2007 → Mar 2014 | acromegaly | Cedars-Sinai Medical Center | Completed | Missed primary |
| Phase 4 | NCT01424241 | Oct 2006 → Mar 2013 | acromegaly | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT00376064 | Mar 2006 → Jan 2010 | acromegaly | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00171613 | Feb → Oct 2005 | acquired hypothalamic obesity | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00242541 | Mar 2003 → Aug 2005 | acromegaly | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT00050635 | Dec 2002 → Jul 2003 | diarrheal disease, neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00145405 | Sep 2002 → Dec 2004 | acromegaly | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00171886 | Jul 2002 → May 2006 | acromegaly | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00521300 | Sep 1999 → Jun 2005 | acromegaly | St. Olavs Hospital | Completed | Missed primary |
| Phase not applicable14 trials · 2 met primary | ||||||
| — | NCT03891849 | Sep 2021 → May 2023 | esophageal varices with bleeding | Centre Hospitalier Universitaire, Amiens | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT04522297 | Apr 2018 → Jan 2020 | hepatorenal syndrome | National Hepatology & Tropical Medicine Research Institute | Completed | No outcome recorded |
| — | NCT03398941 | Feb 2018 → Jan 2019 | pancreas disorder | Chengfeng Wang | Unknown | No outcome recorded |
| — | NCT02381249 | Mar 2015 → Mar 2018 | gastric neoplasm, neoplasm of esophagus, nutritional disorder, pancreatic neoplasm +1 | St. James's Hospital, Ireland | Completed | No outcome recorded |
| — | NCT02920567 | Jan 2014 → Jun 2018 | — | Saint Vincent's Hospital, Korea | Unknown | No outcome recorded |
| — | NCT02385617 | Jan 2014 → Dec 2017 | gastric neoplasm, neoplasm of esophagus, nutritional deficiency disease | St. James's Hospital, Ireland | Completed | Met primary |
| — | NCT01865760 | Jun 2013 → Mar 2016 | hypoglycemia, obesity disorder | University of Aarhus | Completed | No outcome recorded |
| — | NCT01400100 | Aug 2011 → Feb 2012 | pancreas disorder | St. Josef Hospital Bochum | Completed | Met primary |
| — | NCT00652379 | Jun 2008 → Nov 2009 | acromegaly, glucose intolerance | University of Aarhus | Completed | No outcome recorded |
| — | NCT06080204 | Mar 2008 → Apr 2020 | digestive system neuroendocrine tumor, grade 1/2 | Changhai Hospital | Completed | No outcome recorded |
| — | NCT00399893 | Dec 2006 → Apr 2009 | Prader-Willi syndrome | Duke University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01029275 | Jan 2005 → Jan 2012 | acromegaly | University Hospital, Rouen | Completed | No outcome recorded |
| — | NCT00002252 | — | HIV infectious disease, diarrheal disease | Sandoz | Completed | No outcome recorded |
| — | NCT00002253 | — | HIV infectious disease, diarrheal disease | Sandoz | Completed | No outcome recorded |
| Comparator or background therapy63 trials | ||||||
| Phase 0 | NCT03520569 Comparator | Feb 2019 → Apr 2021 | arterial disorder | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT06558422 Background | Jan 2027 → Dec 2028 expected | hyperinsulinism, metabolic dysfunction-associated steatotic liver disease, obesity disorder, prediabetes syndrome | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06881888 Comparator | Aug 2026 → Dec 2027 expected | diabetic macular edema | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07663318 Comparator | Jun → Jul 2026 | acromegaly | Triastek (Shanghai) Limited | Completed | No outcome recorded |
| Phase 1 | NCT06592261 Background | Sep 2024 → Sep 2026 overdue | hyperinsulinism, obesity disorder | Columbia University | Recruiting | No outcome recorded |
| Phase 1 | NCT06126354 Background | Jul 2024 → Nov 2025 | NAFLD1, prediabetes syndrome | Columbia University | Withdrawn | No outcome recorded |
| Phase 1 | NCT05724134 Background | Aug 2023 → Sep 2025 | NAFLD1, hyperinsulinism, obesity disorder, prediabetes syndrome | Columbia University | Completed | No outcome recorded |
| Phase 1 | NCT03879694 Background | Jun 2019 → Feb 2025 | atypical carcinoid tumor, lung carcinoid tumor, pancreatic neuroendocrine tumor | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03057509 Background | Nov 2018 → Oct 2019 | carcinoid tumor | Massachusetts General Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03571594 Comparator | Jun 2018 → May 2019 | acromegaly | Ono Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT02237053 Comparator | Sep 2014 → Jun 2015 | abnormality of glucagon secretion, obesity disorder | AdventHealth Translational Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01871844 Comparator | Jan → Sep 2012 | — | Italfarmaco | Completed | No outcome recorded |
| Phase 1 | NCT01204476 Background | Oct 2010 → Jul 2014 | PPoma, cutaneous neuroendocrine carcinoma, gastrin-producing neuroendocrine tumor, glucagonoma +5 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01561066 Comparator | Jan 2008 → Jan 2012 | intestinal fistula | Jinling Hospital, China | Completed | No outcome recorded |
| Phase 2 | NCT06865677 Background | Jun → Jul 2025 | cervical carcinoma, endometrial carcinoma, ovarian carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT06326190 Comparator | Mar 2025 → Apr 2027 expected | meningioma | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 2 | NCT06505395 Comparator | Jul 2024 → Aug 2027 expected | digestive system neuroendocrine neoplasm | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT04941911 Comparator | May 2022 → Oct 2023 | kidney failure | University College, London | Unknown | No outcome recorded |
| Phase 2 | NCT04048707 Comparator | Jul 2021 → Jun 2023 | acute kidney injury, cirrhosis of liver, hepatorenal syndrome | University of California, Los Angeles | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03967249 Background | Jul 2019 → Mar 2022 | acromegaly | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02795858 Background | Jun 2016 → Dec 2022 | carcinoid tumor | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT02736448 Background | May 2016 → Aug 2019 | digestive system neuroendocrine neoplasm | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Terminated | No outcome recorded |
| Phase 2 | NCT02111044 Comparator | Apr 2014 → Feb 2016 | acromegaly | Italfarmaco | Completed | No outcome recorded |
| Phase 2 | NCT00853047 Background | Mar 2009 → Jun 2014 | carcinoid syndrome | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00427349 Background | Nov 2008 → Oct 2014 | carcinoid tumor, digestive system neuroendocrine neoplasm, neoplastic syndrome | Eastern Cooperative Oncology Group | Completed | Met primary |
| Phase 2 | NCT00466856 Background | Dec 2003 → Oct 2006 | head and neck cancer, metastatic malignant neoplasm, pancreatic neuroendocrine tumor, pheochromocytoma | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04329039 Comparator | Nov 2020 → May 2027 | pancreas disorder | Mayo Clinic | Suspended | No outcome recorded |
| Phase 2/3 | NCT01744249 Background | Nov 2011 → Dec 2023 | neuroendocrine neoplasm | Spanish Group for Research in Neuroendocrine Tumors | Completed | Missed primary |
| Phase 2/3 | NCT00426153 Comparator | Jan 2007 → Oct 2008 | autosomal dominant polycystic kidney disease, autosomal dominant polycystic liver disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT06878664 Background | Jun 2025 → Jan 2029 expected | intestinal neuroendocrine neoplasm | Spanish Group for Research in Neuroendocrine Tumors | Recruiting | No outcome recorded |
| Phase 3 | NCT07057622 Comparator | Dec 2023 → Nov 2026 expected | — | HTA Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05884255 Comparator | Jul 2023 → Dec 2026 expected | digestive system neuroendocrine neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05459844 Comparator | Aug 2022 → Jun 2024 overdue | neuroendocrine neoplasm | Sinotau Pharmaceutical Group | Active not recruiting | Met primary |
| Phase 3 | NCT05477576 Comparator | Mar 2022 → Dec 2026 expected | carcinoid tumor, pancreatic neuroendocrine tumor | RayzeBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03972488 Comparator | Jan 2020 → Jul 2023 overdue | digestive system neuroendocrine neoplasm | Advanced Accelerator Applications | Active not recruiting | Met primary |
| Phase 3 | NCT03252353 Comparator | Sep 2017 → Jun 2019 | acromegaly | Chiasma, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT03000946 Comparator | May 2017 → Feb 2021 | pancreas disorder | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 3 | NCT02384122 Comparator | Sep 2015 → Jul 2022 | anemia, angiodysplasia, vascular malformation | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02457156 Background | Apr 2015 → Jul 2018 | malignant pancreatic neoplasm | University of Liverpool | Completed | No outcome recorded |
| Phase 3 | NCT01137682 Comparator | Jul 2010 → Jan 2013 | acromegaly | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00765323 Comparator | Sep 2008 → Feb 2011 | acromegaly | Endo USA Inc., a Keenova Therapeutics Company | Terminated | No outcome recorded |
| Phase 3 | NCT00690430 Comparator | Apr 2008 → Apr 2012 | carcinoid syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00600886 Comparator | Feb 2008 → Mar 2016 | acromegaly | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00616551 Comparator | Apr 2007 → Feb 2008 | acromegaly | Ambrilia Biopharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00412061 Background | Dec 2006 → Apr 2010 | carcinoid syndrome, carcinoid tumor | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00002864 Comparator | Sep 1996 → Dec 2007 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 4 | NCT06974344 Comparator | Jun 2025 → May 2030 expected | — | King Faisal Specialist Hospital & Research Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05701241 Comparator | Jun 2023 → Apr 2029 expected | digestive system neuroendocrine neoplasm | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Phase 4 | NCT05682209 Comparator | Dec 2020 → Nov 2021 | — | Ikechukwu Bartholomew Ulasi | Completed | No outcome recorded |
| Phase 4 | NCT04028323 Comparator | Jul 2019 → Jul 2020 | esophageal varices with bleeding, impaired renal function disease | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03455322 Comparator | Aug 2018 → Apr 2020 | hepatorenal syndrome | National Hepatology & Tropical Medicine Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02119884 Comparator | Feb 2014 → Jun 2016 | varicose disease | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00595140 Comparator | Jan → Mar 2008 | acromegaly | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT00966355 Comparator | Sep 2006 → May 2010 | esophageal varices with bleeding | Korea University | Completed | No outcome recorded |
| Phase 4 | NCT00534677 Comparator | May 2004 → Jul 2005 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | Aga Khan University | Completed | No outcome recorded |
| Phase 4 | NCT01371643 Comparator | Apr 2004 → Jul 2010 | pituitary gland adenoma | NYU Langone Health | Completed | No outcome recorded |
| — | NCT07460908 Comparator | May → Oct 2025 | hepatorenal syndrome | Lahore General Hospital | Completed | No outcome recorded |
| — | NCT03061604 Background | Nov 2014 → Nov 2017 | varicose disease | Theodor Bilharz Research Institute | Completed | No outcome recorded |
| — | NCT02474914 Comparator | May 2014 → Apr 2017 | carcinoma | Mansoura University | Completed | No outcome recorded |
| — | NCT02123576 Background | Apr 2014 → Dec 2017 | hepatorenal syndrome | Patrick Northup, MD | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02010385 Comparator | Feb 2013 → Jun 2018 | — | University College Dublin | Completed | No outcome recorded |
| — | NCT02305069 Background | Oct 2009 → Oct 2011 | muscular atrophy, obesity disorder | University of Nottingham | Completed | No outcome recorded |
| — | NCT01613495 Comparator | Aug 2005 → Mar 2024 | Prader-Willi syndrome | Oregon Health and Science University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 31
| Date | Issuer | Release |
|---|---|---|
| 2026-07-17 | Camurus AB | Regulatory Camurus’ NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. |
| 2026-07-15 | Camurus AB | Regulatory Camurus’ Interim Report Second Quarter 2026 camurus.com ↗
Complete Response Letter received from the FDA for CAM2029 NDA for acromegaly in the US |
| 2026-06-18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION (SYHX2008) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗
OCTREOTIDE LONG-ACTING INJECTION (SYHX2008) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. |
| 2026-06-10 | Camurus AB | Regulatory Camurus provides regulatory update on the US NDA for CAM2029 (Oclaiz™) in acromegaly camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (Oclaiz™), octreotide extended-release injection, for the treatment of patients with acromegaly. |
| 2026-04-01 | Triastek (Shanghai) Limited | Regulatory Triastek Receives FDA IND Clearance for T25 Octreotide Acetate Tablet triastek.com ↗
Triastek, a pioneer in 3D printed pharmaceutical technology, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for T25 (Octreotide Acetate Tablet), a 3D printed oral peptide product. |
| 2026-01-09 | Camurus AB | Regulatory Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), octreotide extended-release injection, for the treatment of patients with acromegaly. |
| 2025-12-18 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Regulatory Viatris Provides Pipeline Update on Four Regulatory Milestones viatris.com ↗
The U.S. Food and Drug Administration (FDA) has approved the Company's octreotide acetate for injectable suspension, a generic version of Sandostatin ® LAR Depot. |
| 2025-12-10 | Jiangsu HengRui Medicine Co., Ltd. | Results 2025 ESMO Asia回顾｜恒瑞医药19项抗肿瘤研究展现中国创新实力 hengrui.com ↗
基于盲态独立评审委员会（BICR）评估，镥[ 177 Lu]氧奥曲肽组的中位无进展生存期（PFS）尚未达到（95% CI：16.49-未达到），而长效奥曲肽组仅为5.6个月（95% CI：3.12-5.65）。 |
| 2025-08-28 | Camurus AB | Regulatory Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa®, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs. |
| 2025-07-01 | Camurus AB | Regulatory Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly in the EU camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs. |
| 2025-06-18 | Camurus AB | Results Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase 2b study (NCT05281328), evaluating efficacy and safety of octreotide subcutaneous (SC) depot (CAM2029) in patients with symptomatic polycystic liver disease (PLD). |
| 2025-05-15 | Crinetics Pharmaceuticals Inc. | Results Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 crinetics.com ↗
In a three-month daily symptom diary study, patients receiving the long-acting injected depot somatostatin receptor ligands octreotide and lanreotide reported symptom exacerbations on 32% of days. |
| 2025-04-25 | Camurus AB | Regulatory CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU camurus.com ↗
We are pleased with the CHMP’s positive recommendation for market authorization for Oczyesa octreotide monthly depot for the treatment of acromegaly |
| 2024-10-22 | Camurus AB | Regulatory Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly camurus.com ↗
The FDA issues a Complete Response Letter for CAM2029 pending FDA’s assessment of responses from a third-party manufacturer to observations from a recently completed cGMP inspection |
| 2024-09-20 | Camurus AB | Regulatory EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease camurus.com ↗ |
| 2024-07-15 | Camurus AB | Results Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company’s once-monthly octreotide subcutaneous (SC) depot (CAM2029). |
| 2024-05-23 | Camurus AB | Regulatory Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency (EMA) has accepted for review the company’s Market Authorisation Application (MAA) for octreotide subcutaneous (SC) depot (CAM2029) for the treatment of patients with acromegaly. |
| 2024-03-05 | Camurus AB | Regulatory Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for OclaizTM (CAM2029) for the treatment of patients with acromegaly. |
| 2024-01-19 | Novartis Pharmaceuticals | Results Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors novartis.com ↗
In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| 2023-12-21 | Camurus AB | Regulatory Camurus submits New Drug Application to the US FDA for Oclaiz™ for treatment of acromegaly camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OclaizTM (CAM2029), the company’s investigational, once-monthly octreotide subcutaneous (SC) depot for the treatment of patients with acromegaly. |
| 2023-09-25 | Novartis Pharmaceuticals | Results Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) novartis.com ↗ |
| 2023-07-30 | Pharco Pharmaceuticals | Regulatory The Selection and Use of Essential Medicines 2023 pharco.org ↗ |
| 2023-07-17 | Camurus AB | Results Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly camurus.com ↗
The Phase 3 data show a favorable safety profile and robust long-term efficacy over 52 weeks of treatment with CAM2029. |
| 2023-06-20 | Camurus AB | Results Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced positive topline results from a 24-week Phase 3, randomized, double-blind, placebo-controlled trial, ACROINNOVA 1, evaluating the efficacy and safety of the company’s octreotide subcutaneous (SC) depot (CAM2029) in adults with acromegaly. |
| 2023-01-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Octreotide Long-Acting Injection (the “Product”) developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.*（石藥集團中奇製藥技術 （石家莊） 有限公司） , a subsidiary of the Company, has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials for the treatment of acromegaly in China. |
| 2022-03-08 | Ipsen | Results New patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide) ipsen.com ↗
New data presented at ENETS 2022 showed patients treated with Somatuline® Autogel®/Somatline® Depot (lanreotide) pre-filled syringe reported less frequent injection-site pain lasting more than two days than those treated with octreotide long-acting release syringe |
| 2021-09-16 | Camurus AB | Regulatory FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease camurus.com ↗
Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s investigational medicinal product, octreotide subcutaneous depot (CAM2029), for the treatment of autosomal dominant polycystic liver disease. |
| 2020-01-30 | RANI Therapeutics | Results Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill™ ranitherapeutics.com ↗
The Phase I study successfully achieved both its primary and secondary endpoints, demonstrating the safety and tolerability of Octreotide-RP, the RaniPill™ loaded with octreotide, and high oral bioavailability of the biologic drug. |
| 2019-06-20 | Camurus AB | Regulatory Camurus receives IND acceptance from the FDA to enter Phase 3 with CAM2029 for treatment of acromegaly camurus.com ↗
We are pleased to receive the IND approval and will now proceed to starting the pivotal Phase 3 study of CAM2029 octreotide subcutaneous depot for the treatment of acromegaly,” said Fredrik Tiberg, President & CEO of Camurus. |
| 2018-06-07 | Novartis Pharmaceuticals | Results Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs novartis.com ↗
The data demonstrate that treatment with Lutathera provides significantly longer time to deterioration of quality of life for patients with progressive midgut Neuroendocrine tumors (NETs) compared to octreotide LAR alone[1]. |
| 2016-07-12 | Camurus AB | Results Camurus announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors camurus.com ↗
In the present study, treatment with CAM2029 resulted in therapeutic blood-levels of octreotide over four weeks. |
All press releases naming this drug 38 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 205 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octreotide | “Octreotide, an analog of somatostatin, a synthetic form of the hypothalamic hormone somatostatin, which inhibits growth hormone (GH) release by blocking somatostatin receptors...” NCT01424241 ↗182“Patients were randomly assigned (1:1) to axitinib 5 mg or placebo, both orally twice a day, in combination with intramuscular octreotide long-acting release 30 mg once every 28...” PMID 41719493 ↗ Feb 2026 “In total, 136 patients will be randomized in a 2:1 ratio to [177Lu]Lu-DOTATATE (≤4 doses of 7.4 GBq given every 4 wk) or local standard of care (hydroxyurea, bevacizumab,...” PMID 40774695 ↗ Jan 2026 “The medical treatment is based on proglycem, or diazoxide, then octreotide (Sandostatine ®, Novartis) with a dose of 10 to 50 µg/Kg/jour divided to three subcutaneous injections.” NCT00987168 ↗ “Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.” PMID 38662619 ↗ Apr 2024 “Somatostatin analog (octreotide long-acting release (LAR) 30 mg or lanreotide 120 mg) will be given every four weeks for a duration of 18 months.” NCT05701241 ↗ “A pilot study suggested that the somatostatin analogue octreotide longacting release (LAR) could be nephroprotective in this context.” PMID 23972263 ↗ Aug 2013 “Antibiotics along with octreotide, which works by inhibiting pancreatic secretions, is standard treatment for a pancreatic fistula.” NCT04329039 ↗ “The active ingredient in CAM2029, octreotide, is administered as a subcutaneous depot using Camurus' FluidCrystal® technology.” NCT05281328 ↗ “The somatostatin analogue octreotide (Sandostatin®, Novartis) contains 8 amino acids and is very similar to SST-14.” NCT00175305 ↗ “CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection” NCT05050942 ↗ |
| Known as | C2L-OCT-01 PR | “a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR” NCT00635765 ↗ |
| Known as | CAM2029 | “CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection” NCT05050942 ↗ |
| Known as | LAO | “METHODS: A randomized, double-blinded, placebo-controlled trial was designed to determine the efficacy of long-acting octreotide acetate (LAO) in preventing the onset of acute...” PMID 20339140 ↗ Mar 2010 |
| Known as | LAR octreotide | “LAR octreotide (20 mg monthly)” PMID 19886987 ↗ Nov 2009 |
| Known as | Long-acting octreotide | “long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks” NCT00953394 ↗1“Long-acting octreotide” NCT01188733 ↗ |
| Known as | MYCAPSSA | “Orally Administrated Octreotide Acetate Tablets (T25) and Orally Administrated Octreotide Acetate Delayed-Release Capsules (MYCAPSSA®)” NCT07663318 ↗ |
| Known as | OCT | “Octreotide (OCT) has been successfully used for treatment of acromegaly and neuroendocrine tumors for more than 30 years.” PMID 29116540 ↗ Nov 20171“Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation” NCT00990535 ↗ |
| Known as | OctLAR | “Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs).” PMID 35724357 ↗ Jun 20221“octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth” PMID 22773240 ↗ Jul 2012 |
| Known as | octreotide acetate | “The purpose of the study is to investigate the drug octreotide acetate in a new intranasal formulation and compare it to the FDA-approved subcutaneous (SC) injection formulation.” NCT03031535 ↗21“Orally Administrated Octreotide Acetate Tablets (T25) and Orally Administrated Octreotide Acetate Delayed-Release Capsules (MYCAPSSA®)” NCT07663318 ↗ “long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks” NCT01203306 ↗ “a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR” NCT00635765 ↗ “Octreotide acetate 30 mg suspension” NCT00372697 ↗ “Octreotide acetate in microspheres” NCT00248131 ↗ “Sandostatin (Octreotide Acetate)” NCT02427295 ↗ “Drug: octreotide acetate” NCT00033605 ↗ “Drug: octreotide acetate” NCT00002779 ↗ “Drug: Octreotide Acetate” NCT04129255 ↗ “Drug: octreotide acetate” NCT00913055 ↗ |
| Known as | Octreotide acetate LAR | “Octreotide acetate LAR 30 MG” NCT01086982 ↗ |
| Known as | Octreotide LAR | “Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular...” NCT03972488 ↗9“Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut...” PMID 19704057 ↗ Aug 2009 “Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。” NCT06080204 ↗ “to 3 year treatment with two 20 mg intramuscular injections of octreotide-LAR (n=40) or 0·9% sodium chloride solution (n=39) every 28 days.” PMID 23972263 ↗ Aug 2013 “Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)” NCT00002864 ↗ “NCIC CTG MA.14 and NSABP B-29 trials examined the addition of Octreotide LAR (OCT) to 5 years of tamoxifen (TAM).” PMID 26276354 ↗ Aug 2015 “Octreotide LAR is approved for treatment of acromegaly after surgery if the disease is not controlled.” NCT00128232 ↗ “Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection” NCT05050942 ↗ “long-acting somatostatin analogue (Octreotide LAR) compared with placebo” NCT01377246 ↗ “plus Octreotide LAR (20 mg monthly)” NCT00953394 ↗ |
| Known as | OCTREOTIDE LONG-ACTING RELEASE | “Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs).” PMID 35724357 ↗ Jun 20221“OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)” NCT04129255 ↗ |
| Known as | octreotide longacting release (LAR) | “A pilot study suggested that the somatostatin analogue octreotide longacting release (LAR) could be nephroprotective in this context.” PMID 23972263 ↗ Aug 2013 |
| Known as | Octreotide Microspheres | “Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort.” NCT07623824 ↗1“Octreotide Microspheres (Sandostatin LAR@)” NCT06505395 ↗ |
| Known as | octreotide pamoate | “octreotide pamoate (SMS 201-995 pa LAR) intramuscularly (IM) every 21 days for 4 doses” NCT00002967 ↗ |
| Known as | Sandostatin | “The other 2 cohorts are octreotide long-acting release ( Sandostatin LAR® ) 20 mg and Sandostatin® 0.1 mg.” NCT05761431 ↗6“100 mcg of octreotide (Sandostatin®) will be injected intravenously.” NCT03798912 ↗ “Sandostatin (Octreotide Acetate)” NCT02427295 ↗ |
| Known as | Sandostatin LAR | “Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。” NCT06080204 ↗6“Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide.” NCT02294786 ↗ “The other 2 cohorts are octreotide long-acting release ( Sandostatin LAR® ) 20 mg and Sandostatin® 0.1 mg.” NCT05761431 ↗ “Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort.” NCT07623824 ↗ “the first dose of long-acting octreotide (Sandostatin LAR) depot will be given intramuscularly” NCT00257426 ↗ “Sandostatin LAR ® (octreotide acetate LAR) 30 MG” NCT01086982 ↗ “Octreotide Microspheres (Sandostatin LAR@)” NCT06505395 ↗ |
| Known as | Sandostatin LAR Depot | “Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular...” NCT03972488 ↗2“A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity...” NCT00075868 ↗ “The purpose of this study is to learn more about how octreotide (Sandostatin LAR® Depot) affects levels of ghrelin, hunger, and body weight in people with Prader-Willi Syndrome.” NCT01613495 ↗ |
| Known as | Sandostatin LP | “patients with IPF will receive an intramuscular injection of slow release octreotide (Sandostatin LP, 30 mg)every 4 weeks for 48 weeks.” NCT00463983 ↗ |
| Known as | SMS 201-995 pa LAR | “Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)” NCT00002864 ↗1“octreotide pamoate (SMS 201-995 pa LAR) intramuscularly (IM) every 21 days for 4 doses” NCT00002967 ↗ |
| Known as | SMS995 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00584298 ↗ |
| Known as | Somatostatin | “Somatostatin (octreotide)” NCT00386984 ↗ |
| Known as | SYHX2008 | “either SYHX2008（octreotide long-acting injection) or placebo at dose of 5 mg” NCT05761431 ↗ |
| Known as | T25 | “Orally Administrated Octreotide Acetate Tablets (T25) and Orally Administrated Octreotide Acetate Delayed-Release Capsules (MYCAPSSA®)” NCT07663318 ↗ |
| Action | Inhibit | “Octreotide Depot may also help to block certain proteins that are important in tumor growth.” NCT00113360 ↗ |
| Modality | Peptide | “octreotide, a somatostatin octapeptide analog” NCT00004327 ↗ |
| Route | Subcutaneous | “receive a test dose of octreotide subcutaneously on day 1” NCT00002779 ↗ |